Related Experiment Video

Updated: Jun 13, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go?

Becky Woodruff1, Bruce Sullenger, Richard C Becker

  • 1Cardiovascular Thrombosis Research Center, Duke Clinical Research Institute, Duke Translational Research Institute, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27715, USA.

Current Cardiology Reports
|May 1, 2010
PubMed

Insights

Thrombosis is key in advanced coronary artery disease. Understanding the contact system and intrinsic coagulation pathway (factors XI, XII, IX) may lead to new antithrombotic therapies for acute coronary syndrome.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Thrombosis significantly impacts advanced atherosclerotic coronary artery disease.
  • The precise biochemical differences between hemostasis and thrombosis in acute coronary syndrome require further elucidation.

Purpose of the Study:

  • To explore the role of the contact system and intrinsic coagulation pathway in arterial thrombosis.
  • To discuss factors XI, XII, and IX in relation to antithrombotic therapy.

Main Methods:

  • Review of existing literature on the contact system and intrinsic coagulation pathway.
  • Analysis of biochemical properties and pathobiological roles of factors XI, XII, and IX.
  • Examination of their relationship to arterial thrombosis phenotypes.

Main Results:

  • The contact system and intrinsic pathway are implicated in acute coronary syndrome.
  • Factors XI, XII, and IX play crucial roles in coagulation and arterial thrombosis.
  • Understanding these factors offers potential for targeted pharmacotherapy.

Conclusions:

  • Targeting the contact system and intrinsic pathway (factors XI, XII, IX) represents a promising strategy for novel antithrombotic treatments.
  • Further research into these specific coagulation factors is warranted for developing advanced therapies for acute coronary syndrome.

More Related Videos

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation01:06

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...